Production of humanized monoclonal antibodies against Bacillus anthracis and Yersenia pestis for the urgent prophalaxis and therapy of exposed individuals
Battelle Columbus Operations (BCO) has a long-term interest in biomedical defense. The Biodefense Medical Systems Product Line, managed by Dr. John Wade, is devoted to all aspects of medical defense against biological agents. The project will provide synergism with the current programs of BCO and provide IP that can be developed to close critical gaps in the US defense against a bioterrorist attack. The project will also provide access to a number of monoclonal antibodies that could prove to be of crucial importance to the effective response during the recovery from a bioterrorist attack. Advances in technology developed during this project will be of direct benefit to BCO and the US population as a whole.